| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Gedunin targets Hsp90 (heat shock protein 90), a molecular chaperone essential for the folding and stability of many client proteins involved in cancer cell growth and survival. By inhibiting Hsp90, gedunin induces the degradation of Hsp90-dependent client proteins. It has also been shown to alter the sonic hedgehog signaling pathway.
|
|---|---|
| ln Vitro |
Gedunin (0.5-30 μM) has an IC50 value of 16.83 μM, which allows for quantitative regulation of the inhibition of CaCo-2 floating[1].
In vitro, gedunin displays antiproliferative activity in several cancer cell lines with IC50 values of 3.22 µM in SKBr3, 8.84 µM in MCF-7, and 16.8 µM in CaCo-2 cancer cells. It inhibits pancreatic cancer by altering the sonic hedgehog signaling pathway and has been shown to cause apoptosis in A549 lung cancer cells. |
| ln Vivo |
In vivo, gedunin has been studied for its anticancer effects in preclinical models. As an Hsp90 inhibitor, it has the potential to inhibit tumor growth. Its antimalarial activity suggests it could be effective in vivo against Plasmodium parasites. Further in vivo studies are needed to fully characterize its therapeutic potential and pharmacokinetic properties in animal models.
|
| Enzyme Assay |
The in vitro enzyme inhibition assay for gedunin measures its ability to inhibit Hsp90 ATPase activity. The assay is typically performed using purified Hsp90 protein and a suitable substrate. The compound's ability to inhibit the ATPase activity is measured, and its IC50 is determined. Additionally, the induction of Hsp90 client protein degradation can be assessed by Western blot analysis.
|
| Cell Assay |
In vitro cellular studies are conducted using various cancer cell lines, including SKBr3, MCF-7, CaCo-2, and A549 cells. Cells are treated with gedunin at various concentrations for defined time periods. Cell viability is assessed using MTT or other assays to determine the IC50. Apoptosis is measured by detecting caspase activation or using Annexin V staining. The degradation of Hsp90 client proteins is confirmed by Western blot.
|
| Animal Protocol |
In vivo animal experiments are performed using xenograft models of cancer. Tumor-bearing mice are administered gedunin via various routes. Tumor volume is measured over time, and endpoints include tumor growth inhibition and survival. Pharmacodynamic studies evaluate Hsp90 inhibition and client protein degradation in tumor tissues. However, detailed in vivo protocols for gedunin are less commonly reported in the provided literature.
|
| ADME/Pharmacokinetics |
Gedunin has a molecular formula of C28H34O7 and a molecular weight of 482.57 g/mol. It is a natural product isolated from neem seeds. It is soluble in DMSO and ethanol. For research, it is typically stored as a powder at -20°C, protected from light and moisture. Its purity is generally high for research-grade material.
|
| Toxicity/Toxicokinetics |
Toxicological data for gedunin are derived from preclinical studies. As a natural compound with potent biological activity, it is for research use only and not intended for human therapeutic applications. Its safety profile in animals would need to be established through comprehensive toxicology studies. Standard laboratory safety precautions should be followed when handling it.
|
| References |
|
| Additional Infomation |
Gedunin is a pentacyclic triterpenoid natural product, primarily found in Azadirachta indica and Cedrela odorata. It possesses activities including antimalarial, antitumor, Hsp90 inhibitor, and phytometrogenic activity. Gedunin is a limonene compound, an acetate compound, an epoxide compound, an enone compound, a furan compound, a pentacyclic triterpenoid compound, an organopentacyclic compound, and a lactone compound. It has also been reported to exist in Cedrela salvadorensis, Melia azedarach, and other organisms with relevant data.
Gedunin is a prominent limonoid from the neem tree with a wide range of biological activities, including anticancer, antiviral (SARS-CoV-2), anti-inflammatory, and antimalarial effects. It is a valuable tool for studying the Hsp90 chaperone pathway and its role in cancer and infectious diseases. It is supplied as a powder with high purity for research purposes. |
| Molecular Formula |
C28H34O7
|
|---|---|
| Molecular Weight |
482.56536
|
| Exact Mass |
482.23
|
| CAS # |
2753-30-2
|
| PubChem CID |
12004512
|
| Appearance |
White to off-white solid powder
|
| Density |
1.28g/cm3
|
| Boiling Point |
594.3ºC at 760mmHg
|
| Flash Point |
313.2ºC
|
| Vapour Pressure |
4.31E-14mmHg at 25°C
|
| Index of Refraction |
1.581
|
| LogP |
4.56
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
35
|
| Complexity |
1030
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
CC(=O)O[C@@H]1C[C@@H]2[C@](C=CC(=O)C2(C)C)([C@@H]3[C@@]1([C@]45[C@H](O4)C(=O)O[C@H]([C@@]5(CC3)C)C6=COC=C6)C)C
|
| InChi Key |
YJXDGWUNRYLINJ-BHAPSIHVSA-N
|
| InChi Code |
InChI=1S/C28H34O7/c1-15(29)33-20-13-18-24(2,3)19(30)8-10-25(18,4)17-7-11-26(5)21(16-9-12-32-14-16)34-23(31)22-28(26,35-22)27(17,20)6/h8-10,12,14,17-18,20-22H,7,11,13H2,1-6H3/t17-,18+,20-,21+,22-,25-,26+,27+,28-/m1/s1
|
| Chemical Name |
[(1S,2R,4S,7S,8S,11R,12R,17R,19R)-7-(furan-3-yl)-1,8,12,16,16-pentamethyl-5,15-dioxo-3,6-dioxapentacyclo[9.8.0.02,4.02,8.012,17]nonadec-13-en-19-yl] acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0722 mL | 10.3612 mL | 20.7224 mL | |
| 5 mM | 0.4144 mL | 2.0722 mL | 4.1445 mL | |
| 10 mM | 0.2072 mL | 1.0361 mL | 2.0722 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
